The latest study on ‘Global Oncology/Cancer Blockbuster Drugs Market Research Report 2019 – 2025’, available with Market Study Report, aims to educate the readers about the promising drugs in oncology/cancer vertical and their growth scope over 2020-2025.
 

As per the report, global oncology/cancer blockbuster drugs industry is projected to amass USD 120 billion by the year 2025. It lays the forthcoming roadmap for market growth by analyzing the historical evidences from 2015-2018, prevalent catalysts and opportunities, as well as challenges & restraints presently dormant.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1868453/
 

The business intelligence document entails 27 blockbuster drugs, namely, Faslodex, Neulasta, Sandostatin, Exjade Jadenu, Tasigna, Afinitor/Votubia, Xgeva, Alimta, Velcade, Gleevec/Glivec, Xtandi, Yervoy, Jakafi/Jakavi, Zytiga, Darzalex, Tagrisso, Opdivo, Ibrance, Sprycel, Avastin, Perjeta, MabThera/Rituxan, Imbruvica, Pomalyst/Imnovid, Revlimid, Keytruda, and Herceptin. It further goes ahead to reveal the product demand, and industry share held by each product type over the analysis timeframe.
 

A thorough scrutiny of the latest development in the industry sphere, including licensing agreements, mergers & acquisitions, partnerships & collaborations, as well as distribution deals employed by businesses to stay ahead of competition and guarantee profit inflow, is presented in the report.
 

These industry behemoths, who are capable to influencing the global oncology/cancer blockbuster drugs market dynamics include Amgen Inc., Novartis International AG, Celgene Corp., AstraZeneca plc, Johnson & Johnson, Merck & Co. Inc., Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb, and Roche Holding AG among others.
 

Lastly, the worldwide oncology/cancer blockbuster drugs market report leverages expert insights to offer information pertaining to estimated revenue generation by different drugs, hence enabling investors to take informed decisions.